NLS Pharmaceutics AG: NLS Pharmaceutics Announces Positive Interim Top-Line Data for Quilience (Mazindol ER) in Patients with Narcolepsy
Clinically meaningful results with Mazindol ER exhibiting a 39% reduction in ESS from baseline (-4.3 points placebo-adjusted); confirms statistical powering of the ongoing Phase 2a trialSafety and tolerability
Source: finanznachrichten.de